Close
Achema middle east
swop processing & packaging

Sanofi Files For Hart-Scott-Rodino Notification Regarding Proposed Acquisition Of Medivation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

UK Exchequer Wants More Pharma Investment Coming in Britain

Rachel Reeves, the UK Chancellor of the Exchequer, has...

Advanced Drug Delivery Platforms Enhancing Bioavailability

Enhancing Bioavailability Through Advanced Drug Delivery Platforms The pharmaceutical industry...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation

Sanofi announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its intention to acquire Medivation, Inc. (NASDAQ: MDVN).  As announced on April 28, 2016, Sanofi proposed to acquire Medivation for $52.50 per share, representing an all-cash transaction valued at approximately $9.3 billion.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris

Media Relations
Jack Cox and Laurence Bollack
Tel. : +33 (0)1 53 77 46 46
mr@sanofi.com

Investor Relations
Sébastien Martel
Tel.: +33 (0)1 53 77 45 45

George Grofik
Tel.: + 1 908-981-5560
ir@sanofi.com

 

Latest stories

Related stories

UK Exchequer Wants More Pharma Investment Coming in Britain

Rachel Reeves, the UK Chancellor of the Exchequer, has...

Advanced Drug Delivery Platforms Enhancing Bioavailability

Enhancing Bioavailability Through Advanced Drug Delivery Platforms The pharmaceutical industry...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »